Trial Profile
A Multipart Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human, Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation (Part 1); After Multi-Day Dosing (Part 2) in Healthy Subjects; and After Multiple (Ascending) Doses in Subjects With Chronic Hepatitis B (Part 3)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs JNJ-440 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Alios BioPharma
- 18 Jan 2022 Results (n=20) assessing the evaluated the safety, tolerability, antiviral activity and pharmacokinetics of JNJ-64530440 in CHB patients over 28 days, published in the Journal of Antimicrobial Chemotherapy.
- 09 Dec 2019 Status changed from recruiting to completed.
- 22 Jan 2019 Planned End Date changed from 31 Jul 2019 to 31 Dec 2019.